Expedite regulated documents in the era of COVID-19: From development, trials & manufacturing
The COVID-19 pandemic has drastically altered the life sciences industry as global travel restrictions and stay-at-home orders have impacted the ability drug companies to continue ‘as usual’ to get drugs to market. Despite these changes, the development, clinical trials, and manufacturing of therapies still need to hit critical deadlines while ensuring that regulated documents are compliant.
Learn best practices about how to implement effective technological solutions to digitize aspects the pharmaceutical value chain. A key topic will be how to quickly and efficiently attain internal and external signatures that are compliant with the FDA’s 21 Code of Federal Regulations Part 11 regulations and allow trial flexibility such as remotely enrolling patients into clinical trials.
You'll also learn:
- How to create a patient-centric experience to remotely enroll, engage, and medically monitor patients while keeping clinical trials on track
- Best practices to empower a remote workforce with technological innovations that can streamline the regulated documents process
- How to maintain compliance and validation when adapting clinical trial processes to accommodate a remote workforce